
## Lesley C Dupuy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4213699/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A DNA Vaccine for Venezuelan Equine Encephalitis Virus Delivered by Intramuscular Electroporation Elicits High Levels of Neutralizing Antibodies in Multiple Animal Models and Provides Protective Immunity to Mice and Nonhuman Primates. Vaccine Journal, 2011, 18, 707-716.	3.1	75
2	A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine, 2016, 34, 3607-3612.	3.8	51
3	Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice. Molecular Therapy, 2019, 27, 850-865.	8.2	45
4	Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine, 2010, 28, 7345-7350.	3.8	43
5	Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine, 2009, 27, 4152-4160.	3.8	37
6	DNA vaccines for biodefense. Expert Review of Vaccines, 2009, 8, 1739-1754.	4.4	31
7	Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PLoS ONE, 2015, 10, e0137786.	2.5	24
8	An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Human Vaccines and Immunotherapeutics, 2017, 13, 2824-2836.	3.3	21
9	Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule. Comparative Medicine, 2018, 68, 380-395.	1.0	21
10	Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus. Molecular Therapy - Methods and Clinical Development, 2020, 17, 810-821.	4.1	20
11	Nonhuman primate models of encephalitic alphavirus infection: historical review and future perspectives. Current Opinion in Virology, 2012, 2, 363-367.	5.4	19
12	Current Strategic Thinking for the Development of a Trivalent Alphavirus Vaccine for Human Use. American Journal of Tropical Medicine and Hygiene, 2014, 91, 442-450.	1.4	19
13	A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges. Journal of Immunology Research. 2018. 2018. 1-15.	2.2	11
14	Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response. Journal of Virological Methods, 2019, 270, 12-17.	2.1	11
15	The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice. Antiviral Research, 2018, 159, 113-121.	4.1	8
16	The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice. Journal of Infectious Diseases, 2018, 218, S519-S527.	4.0	8
17	Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding. Human Vaccines and Immunotherapeutics, 2017, 13, 2953-2966.	3.3	4